We have 1
[19]:
If this were a game like a chess game, then we would have two points, one point being a short answer, the other being a long answer. However, it is not a game, and the points given for the voting is a personal opinion of the person who voted. If a person votes twice, only the first vote is counted.
Of course, wikimedia gives you an edit count. However, since it is for your own good, it counts only the edit you made. It does not include edits done by other editors. If you want the edit count, use the online count (source: Wikipedia talk:Requests for arbitration/Mav v.. (page does not exist))).
This is not a "whining". It is a fact. See my edits.
Follow-up of patients with myeloma who have completed autologous stem cell transplantation and who then underwent rituximab maintenance therapy.
Patients with multiple myeloma who have had an autologous stem cell transplant may undergo maintenance therapy with rituximab. To determine the efficacy and toxicity of this therapy, the authors reviewed the outcomes of these patients. This study is a retrospective review of patients treated at the Dana-Farber/Harvard Cancer Center who received rituximab in the maintenance setting following an autologous stem cell transplantation. Between December 1999 and December 2003, 39 patients received rituximab after autologous stem cell transplantation. Most patients had received one or two prior regimens of chemotherapy. The median number of prior regimens was 3. Sixteen patients (41%) received 4 or more prior regimens. The median number of days from the completion of the autologous stem cell transplant to the initiation of rituximab maintenance was 230 days (range, 38 to 771 days). Median duration of rituximab maintenance therapy was 28 weeks (range, 12 to 110 weeks). Three patients (8%) received a dose reduction due to neutropenia or thrombocytopenia. The overall response rate was 83%, with two complete and 13 partial responses. Median time to progression was 32 weeks (95% confidence interval, 26 to 40 weeks). Twenty-five patients (64%) had disease progression and 25 died during the follow-up period. At a median follow-up of 33 be359ba680
Related links: